We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.36%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$567M
AUM Growth
+$88.3M
Cap. Flow
+$6.93M
Cap. Flow %
1.22%
Top 10 Hldgs %
70.26%
Holding
36
New
5
Increased
6
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$45.2M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$18M
3
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$14.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$8.25M
5
LOXO
Loxo Oncology, Inc
LOXO
+$6.69M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$20.6M
2
CASC
Cascadian Therapeutics, Inc.
CASC
+$12M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$8.21M
4
EXEL icon
Exelixis
EXEL
+$7.23M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 62.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$66.1M 11.67%
9,169,276
-236,541
-3% -$1.75M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$59.8M 10.56%
7,270,013
-1,033,071
-12% -$8.21M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$41.9M 7.4%
+1,582,408
New +$45.2M
FWP
4
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$38.4M 6.78%
144,140
-24,072
-14% -$5.76M
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$37.5M 6.63%
2,521,452
+1,180,793
+88% +$18M
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
$36.5M 6.44%
1,625,696
-760,000
-32% -$12M
LOXO
7
DELISTED
Loxo Oncology, Inc
LOXO
$29.1M 5.14%
1,615,081
+489,416
+43% +$6.69M
OMED
8
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$28.5M 5.02%
1,264,715
-19,400
-2% -$478K
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$614M
$26.2M 4.62%
2,592,303
– –
VTAE
10
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$23.1M 4.08%
1,604,615
+27,180
+2% +$369K
TBRA
11
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$20.3M 3.58%
1,175,233
+966,064
+462% +$14.1M
GYRE icon
12
Gyre Therapeutics
GYRE
$648M
$18.6M 3.28%
8,451
– –
ONCT
13
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$15.8M 2.79%
7,695
-242
-3% -$344K
QLTI
14
DELISTED
QLT Inc
QLTI
$15.4M 2.72%
3,737,446
-412,416
-10% -$1.58M
CYTK icon
15
Cytokinetics
CYTK
$10.9B
$14.2M 2.5%
2,106,989
– –
EXEL icon
16
Exelixis
EXEL
$14.1B
$10.4M 1.84%
2,766,152
-2,222,205
-45% -$7.23M
ARQL
17
DELISTED
Arqule Inc
ARQL
$10.3M 1.82%
6,430,708
+256,147
+4% +$493K
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$9.68M 1.71%
+200,000
New +$8.25M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.2B
$7.83M 1.38%
678,764
+287,340
+73% +$3.97M
FPRX
20
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.98M 1.05%
240,597
-262,235
-52% -$5.84M
ATXS
21
DELISTED
Astria Therapeutics
ATXS
$2.75M 0.48%
+3,750
New +$2.83M
SVRA icon
22
Savara
SVRA
$1.14B
$2.5M 0.44%
73,018
-30,433
-29% -$1.07M
ATYR
23
aTyr Pharma
ATYR
$47.1M
$2.5M 0.44%
+9,623
New +$2.99M
ACHV icon
24
Achieve Life Sciences
ACHV
$647M
$2.38M 0.42%
464
-158
-25% -$784K
GBIM
25
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$1.77M 0.31%
+678,400
New +$4.22M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2015 Portfolio in Review

As of Q2 2015, BVF Inc held 36 positions worth $567M, up 18% from $478M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc's Q2 2015 filing shows 5 new, 6 increased, 13 reduced and 6 closed positions. Its largest new stake was Blueprint Medicines: 1,582,408 shares worth $41.9M. The largest sale was Ligand Pharmaceuticals, an estimated $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 63% a quarter earlier.

  • BVF Inc's largest Q2 2015 buy was Blueprint Medicines: 1,582,408 shares worth $41.9M.
  • BVF Inc added most to Concert Pharmaceuticals, Inc. in Q2 2015, an estimated $18M increase.
  • BVF Inc's biggest Q2 2015 reduction was Cascadian Therapeutics, Inc., cutting an estimated $12M.
  • BVF Inc fully exited Ligand Pharmaceuticals in Q2 2015, selling an estimated $20.6M.
  • BVF Inc's ten largest holdings make up 70% of its $567M portfolio in Q2 2015.
  • BVF Inc opened 5 new positions and closed 6 in Q2 2015.
  • BVF Inc's portfolio value rose 18% quarter-over-quarter to $567M.

Based on BVF Inc's 13F filing for Q2 2015, filed 14 Aug 2015.